source
- Novo’s stock tumbles after two-year GLP-1 boom as AI drug-discovery startups land huge funding roundsNovo’s shares, which peaked above $140 in June 2024 during a surge in demand for its GLP-1 drugs Ozempic and Wegovy, have fallen sharply over the past two years. The decline reflects a broader mark…
- Novo signs $1.3 billion deal with Nanexa to add long-acting injectables for obesity and diabetesNovo has entered a licensing agreement with Nanexa, valued at about 1.17 billion euros, to use Nanexa’s PharmaShell platform for its obesity and type‑2 diabetes medicines. The PharmaShell technolo…